# Kidney Health Initiative is a public-private partnership between the American Society of Nephrology, US Food and Drug Administration and the kidney community.

> **NIH FDA R18** · AMERICAN SOCIETY OF NEPHROLOGY, INC. · 2024 · $300,000

## Abstract

RFA-FD-24-041
Project Summary/Abstract
The Kidney Health Initiative (KHI) is a public-private partnership among the American
Society of Nephrology (ASN), US Food and Drug Administration (FDA), and all major
constituents in the kidney community (patients, healthcare professionals, members of
industry and government). KHI is the largest consortium in the kidney community and is
focused on addressing barriers to the development of new drugs, devices and biologics
for people with kidney diseases. KHI’s community, governance, and infrastructure
makes it uniquely positioned to convene and identify issues facing the kidney
community, translate them into a pre-competitive collaborative activity, and produce a
consensus deliverable. These resources provide recommendations and direction for
any individual, company, or organization to use for the development of innovative kidney
drugs, devices, and biologics.
The current proposal builds on KHI’s accomplishments and leverages the expertise
within KHI’s Board of Directors, the member community, and ASN to execute projects
that include but are not limited to development and evaluation of clinical trial endpoints,
creation of roadmaps to advance product development, and tools to integrate the
patient perspective in clinical research and product development; convene the
community to define and communicate solutions addressing shared challenges; and
collaborate within and outside of the kidney community to strengthen the impact of KHI
resources. Over the next five years under the direction of KHI’s Board of Directors and
guidance of KHI’s Patient and Family Partnership Council, KHI will continue to advance
its project portfolio and annual meeting. KHI remains a neutral and patient-centered
platform that convenes the kidney community to exchange information and explore pre-
competitive collaborations. To further the community’s evolution, KHI projects and
annual meeting will be supplemented with increased in-depth topical activities including
workshops, virtual convenings, and consistent communications with the member
community. KHI will also pursue outreach opportunities to further adopt or strengthen
KHI resources, support activities and projects led by strategically aligned organizations,
and pursue partnerships with complementary organizations. KHI has spent a decade
building an innovation community, now is the time to increase the depth of solutions that
fill critical gaps impacting progress of kidney innovations.

## Key facts

- **NIH application ID:** 11129513
- **Project number:** 2R18FD005283-11
- **Recipient organization:** AMERICAN SOCIETY OF NEPHROLOGY, INC.
- **Principal Investigator:** Tod Ramses Ibrahim
- **Activity code:** R18 (R01, R21, SBIR, etc.)
- **Funding institute:** FDA
- **Fiscal year:** 2024
- **Award amount:** $300,000
- **Award type:** 2
- **Project period:** 2014-09-01 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11129513

## Citation

> US National Institutes of Health, RePORTER application 11129513, Kidney Health Initiative is a public-private partnership between the American Society of Nephrology, US Food and Drug Administration and the kidney community. (2R18FD005283-11). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11129513. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*